Altimmune’s Stock Trades In A Double Bottom Pattern: What’s Next?
Altimmune Inc. (NASDAQ: ALT) shares traded higher after the company announced data from its ALT-801 Phase 1 Trial in overweight and obese volunteers. The company announced that weight loss of 5.4% was achieved at six weeks with a weekly dose of 1.8mg.